REVENUE (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($) segment	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Number of reportable segments | segment	2
Total revenue, net	$ 30,654	$ 29,511
Contract receivables, current	1,100		$ 1,100
Contract receivables, noncurrent	3,900		3,700
Current portion of deferred revenue, and other	8,200		8,700
Contract liabilities, revenue recognized	1,100
Contract liabilities, increase due to additional deferred sales	$ 600
Average term of underlying contracts	6
Capitalized contract costs	$ 2,700		$ 2,700
Capitalized contract costs, amortization	200
Capitalized contract costs during the period	200
Core companion animal
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	27,306	24,716
Point of Care laboratory revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	17,096	15,961
Consumables
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	14,248	12,317
Sales-type leases
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,244	1,742
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	1,205	1,528
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	399	374
Point of Care imaging revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,855	5,410
Outright instrument sales
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	4,055	4,546
Other
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	800	864
Other CCA revenue:
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	5,355	3,345
Other pharmaceuticals, vaccines and diagnostic tests
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	5,329	3,246
Research and development, license and royalty revenue
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	26	99
Other vaccines and pharmaceuticals
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,348	4,795
Contract manufacturing
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	3,191	4,666
License, research and development
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Total revenue, net	$ 157	$ 129